Abstract
OBJECTIVE: To evaluate the relationship between serum gamma-glutamyl transferase (GGT) levels and fatty pancreas in obese subjects with both insulin resistance and NAFLD without a history of pancreatitis
METHODS: From March 2019 to September 2021, 31 adult subjects with concurrent obesity and NAFLD were recruited as part of the study investigating the biological impact of bariatric surgery and lifestyle modification on obesity. Chemical shift encoded MRI of the abdomen, LiverMultiScan, anthropometric, clinical and blood biochemistry analyses were performed.
RESULTS: GGT (p<001) was significantly different between those ‘with fatty pancreas’ and ‘without fatty pancreas’ groups. GGT (p<0.001) was significantly different between those ‘with both metabolic syndrome and fatty pancreas’ and those ‘with metabolic syndrome but without fatty pancreas.’ GGT (p<0.001) was also significantly different between those ‘with both diabetes and fatty pancreas’ and those ‘with diabetes but without fatty pancreas’. Regression analysis showed that fatty pancreas (p=0.048) and Hypoalphalipoproteinemia (p=0.005), and BMI (p=0.027) were significant independent predictors of abnormal GGT. GGT was associated with fatty pancreas by an odds ratio 7.333 (95% [CI]: 1.467-36.664), while the AUROC of GGT in determining fatty pancreas was 0.849.
CONCLUSIONS: Elevation in serum gamma-glutamyl transferase might be a potential marker to identify fatty pancreas.
METHODS: From March 2019 to September 2021, 31 adult subjects with concurrent obesity and NAFLD were recruited as part of the study investigating the biological impact of bariatric surgery and lifestyle modification on obesity. Chemical shift encoded MRI of the abdomen, LiverMultiScan, anthropometric, clinical and blood biochemistry analyses were performed.
RESULTS: GGT (p<001) was significantly different between those ‘with fatty pancreas’ and ‘without fatty pancreas’ groups. GGT (p<0.001) was significantly different between those ‘with both metabolic syndrome and fatty pancreas’ and those ‘with metabolic syndrome but without fatty pancreas.’ GGT (p<0.001) was also significantly different between those ‘with both diabetes and fatty pancreas’ and those ‘with diabetes but without fatty pancreas’. Regression analysis showed that fatty pancreas (p=0.048) and Hypoalphalipoproteinemia (p=0.005), and BMI (p=0.027) were significant independent predictors of abnormal GGT. GGT was associated with fatty pancreas by an odds ratio 7.333 (95% [CI]: 1.467-36.664), while the AUROC of GGT in determining fatty pancreas was 0.849.
CONCLUSIONS: Elevation in serum gamma-glutamyl transferase might be a potential marker to identify fatty pancreas.
| Original language | English |
|---|---|
| Article number | COB-23-RORE-0211 |
| Pages (from-to) | 1-20 |
| Number of pages | 20 |
| Journal | Clinical obesity |
| DOIs | |
| Publication status | Submitted - 8 Jun 2024 |
